Literature DB >> 1797315

Thermogenic and lipolytic effect of yohimbine in the dog.

J Galitzky1, M Vermorel, M Lafontan, P Montastruc, M Berlan.   

Abstract

1. Lipid mobilization during a hypocaloric diet may be enhanced by a pharmacological approach using alpha 2-adrenoceptor antagonists since these drugs are known to increase sympathetic tone and stimulate lipolysis. Studies were undertaken in the dog in order to evaluate the effects of oral yohimbine administration (alpha 2-adrenoceptor antagonist) on heat production, metabolic, endocrinological and cardiovascular parameters. 2. Acute oral yohimbine (0.25 or 0.40 mg kg-1) provoked an increase in plasma non-esterified fatty acids. The drug increased sympathetic nervous system activity as indicated by the increased level of plasma noradrenaline. These effects persisted during the entire experimental period (4 h). The increase in plasma noradrenaline level was two fold higher with the higher dose of yohimbine (0.4 mg kg-1). The plasma adrenaline level was increased only with the higher dose. 3. Yohimbine transiently increased plasma insulin and the effect was dose-dependent. 4. Yohimbine (0.25 mg kg-1) enhanced heart rate and arterial blood pressure. 5. The effect of yohimbine on oxygen consumption, carbon dioxide and heat production was determined by indirect calorimetry. The drug (0.25 mg kg-1) increased O2 consumption and CO2 and heat production 30 min after its administration and the effect persisted over the experimental period. The respiratory quotient, rather low in the fasting animals, remained unchanged. 6. The present work indicates that thermogenesis and lipid mobilization are enhanced during fasting in the dog by alpha 2-adrenoceptor blockade. Yohimbine also induced a transient increase in plasma insulin level and increased heart rate and blood pressure. The lipid mobilization plus the action on thermogenesis observed after yohimbine draw attention to the putative interest of a2-antagonists in the pharmacological treatment of obesity during restricted calorie intake.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1797315      PMCID: PMC1908559          DOI: 10.1111/j.1476-5381.1991.tb12460.x

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  27 in total

1.  Mechanism of the lipid-mobilizing effect of alpha-2 adrenergic antagonists in the dog.

Authors:  M Taouis; M Berlan; P Montastruc; M Lafontan
Journal:  J Pharmacol Exp Ther       Date:  1988-12       Impact factor: 4.030

2.  Alpha 2-antagonist compounds and lipid mobilization: evidence for a lipid mobilizing effect of oral yohimbine in healthy male volunteers.

Authors:  J Galitzky; M Taouis; M Berlan; D Rivière; M Garrigues; M Lafontan
Journal:  Eur J Clin Invest       Date:  1988-12       Impact factor: 4.686

3.  Characterization of dog fat cell adrenoceptors: variations in alpha-2 and beta adrenergic receptors distribution according to the extent of the fat deposits and the anatomical location.

Authors:  M Taouis; M Berlan; P Montastruc; M Lafontan
Journal:  J Pharmacol Exp Ther       Date:  1987-09       Impact factor: 4.030

4.  The obese dog and some clinical repercussions.

Authors:  J O Joshua
Journal:  J Small Anim Pract       Date:  1970-09       Impact factor: 1.522

5.  Hormone-fuel interrelationships during fasting.

Authors:  G F Cahill; M G Herrera; A P Morgan; J S Soeldner; J Steinke; P L Levy; G A Reichard; D M Kipnis
Journal:  J Clin Invest       Date:  1966-11       Impact factor: 14.808

6.  Effect of short- and long-term beta-adrenergic blockade on lipolysis during fasting in humans.

Authors:  S Klein; E J Peters; O B Holland; R R Wolfe
Journal:  Am J Physiol       Date:  1989-07

7.  Plasma catecholamine levels and lipid mobilization induced by yohimbine in obese and non-obese women.

Authors:  M Berlan; J Galitzky; D Riviere; M Foureau; M A Tran; R Flores; J P Louvet; G Houin; M Lafontan
Journal:  Int J Obes       Date:  1991-05

8.  Thermogenic effect of the new beta-adrenoreceptor agonist Ro 16-8714 in healthy male volunteers.

Authors:  C Henny; Y Schutz; A Buckert; M Meylan; E Jequier; J P Felber
Journal:  Int J Obes       Date:  1987

9.  Weight loss in obese subjects on a restricted diet given BRL 26830A, a new atypical beta adrenoceptor agonist.

Authors:  A A Connacher; R T Jung; P E Mitchell
Journal:  Br Med J (Clin Res Ed)       Date:  1988-04-30

10.  Adrenergic control of lipolysis and metabolic responses in obesity.

Authors:  B Zahorska-Markiewicz; C Kucio; D Piskorska
Journal:  Horm Metab Res       Date:  1986-10       Impact factor: 2.936

View more
  6 in total

Review 1.  Pharmacological approaches for the treatment of obesity.

Authors:  José-Antonio Fernández-López; Xavier Remesar; Màrius Foz; Marià Alemany
Journal:  Drugs       Date:  2002       Impact factor: 9.546

2.  Interactions between an alpha2-adrenergic antagonist and a beta3-adrenergic agonist on the expression of UCP2 and UCP3 in rats.

Authors:  J Gómez-Ambrosi; G Frühbeck; J A Martínez
Journal:  J Physiol Biochem       Date:  2002-03       Impact factor: 4.158

3.  Activation of Anxiogenic Circuits Instigates Resistance to Diet-Induced Obesity via Increased Energy Expenditure.

Authors:  Xiangyang Xie; Haili Yang; Juan Ji An; Jessica Houtz; Ji-Wei Tan; Haifei Xu; Guey-Ying Liao; Zhi-Xiang Xu; Baoji Xu
Journal:  Cell Metab       Date:  2019-01-17       Impact factor: 27.287

4.  Potentiation of the anti-obesity effect of the selective beta 3-adrenoceptor agonist BRL 35135 in obese Zucker rats by exercise.

Authors:  E Santti; R Huupponen; J Rouru; V Hänninen; U Pesonen; M Jhanwar-Uniyal; M Koulu
Journal:  Br J Pharmacol       Date:  1994-12       Impact factor: 8.739

5.  A Comparison of the Anorectic Effect and Safety of the Alpha2-Adrenoceptor Ligands Guanfacine and Yohimbine in Rats with Diet-Induced Obesity.

Authors:  Magdalena Dudek; Joanna Knutelska; Marek Bednarski; Leszek Nowiński; Małgorzata Zygmunt; Barbara Mordyl; Monika Głuch-Lutwin; Grzegorz Kazek; Jacek Sapa; Karolina Pytka
Journal:  PLoS One       Date:  2015-10-27       Impact factor: 3.240

6.  Acute oral intake of a higenamine-based dietary supplement increases circulating free fatty acids and energy expenditure in human subjects.

Authors:  Sang-Rok Lee; Johnhenry M Schriefer; Trint A Gunnels; Innocence C Harvey; Richard J Bloomer
Journal:  Lipids Health Dis       Date:  2013-10-21       Impact factor: 3.876

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.